There's One GOP Senator Who Knows the Dangers of Letting This BBB Provision...
Here's What Senate Dems Plan to Do to Gum Up the Works for...
Well, We Knew This GOP Senator Was Going to Screw Us
Supreme Court Made a Surprising Move in the Louisiana Redistricting Case Yesterday
Hegseth Reveals the Official New Name of the USNS Harvey Milk
Sabotage? Schumer Drags Out Trump’s BBB With All-Night Stunt to Delay GOP Victory
DHS Raids Los Angeles Home Tied to Iranian Smuggling Ring; Terror Watchlist Suspects...
Senate Gears Up to Vote on Trump’s ‘Big Beautiful Bill’
Five GOP Lawmakers Threaten to Tank BBB Over Public Land Sell-Off
Far-Left Comedian Blames Trump for Her Overeating, Alcohol Abuse, and Depression
Ex-Hochul and Cuomo Aide Arrested As Chinese Agent, Kash Patel Calls for Full...
Nowhere to Run: DeSantis’ 'Alligator Alcatraz' Targets Border Crisis with Swamp Security
Did You Catch This Awkward Moment at a WNBA Game This Week?
As Kamala Harris Slips in Support for 2028, Another Top Candidate Also Has...
Cotton Slams ODNI As Bloated Bureaucracy, Pushes Bill to Slash Waste and End...
Tipsheet

Despite Biden Admin Promises of Keeping New Drug Prices Down, Big Pharma Sees Hundreds of Price Hikes

Big Pharma kicked off 2024 with hundreds of price hikes for new drugs despite the Biden Administration’s promises of keeping pharmaceutical costs down. 

According to a report released Friday, pharmaceutical companies set median starting list prices 35 percent higher in 2023 than the previous year. 

Advertisement

In 2022, the median list price for a drug being placed on the market was $222,000. Compare that to 2023, where the median drug price spiked to $300,000 despite the Biden Administration stating one of its goals was to keep pharmaceutical costs affordable for Americans. 

President Joe Biden has announced plans to impose automatic rebates to Medicare for drugmakers that raise their prices faster than the rate of inflation—which does not cover the starting list price— and the President’s Inflation Reduction Act (IRA). However, Pfizer, Sanofi, and Takeda have raised prices on more than 500 drug doses and formulations this month alone. 

More than 140 medicine brands also saw their prices increase in January. 

In November 2021, Biden announced plans to keep drug prices down by putting a cap on the amount senior citizens and people with disabilities have to pay out-of-pocket for their prescriptions. In August of last year, the president vowed that ten drugs would be required to negotiate prices with Medicare or face up to a 95 percent sales tax. 

Pfizer stood out for one of the most extensive January price hikes. Its cost increase was more than a quarter of all medicines included during the time frame. Reuters noted that the company has raised prices on at least 124 doses or formulations. 

Pfizer and Hospira also plan to raise the prices of 30 and six branded drugs later this year. 

Advertisement

In December, the Biden Administration revealed that 48 Medicare Part B drugs raised their prices faster than the inflation rate. This prompted automatic rebates to the government insurance program for payments made over the inflation rate, resulting from the Prescription Drug Inflation Rebate Program by the Department of Health and Human Services (HHS) as part of Biden’s IRA. 

“There are reasons why Medicare and Medicaid have long histories of paying excessive prices for drugs: everyone in those programs is paying with someone else’s money, and nobody spends someone else’s money as carefully as they spend their own,” Michael Cannon, director of health policy studies at the Cato Institute told the DCNF. “That dynamic. Has. Not. Changed. These latest attempts to contain drug prices in Medicare will most likely fail, just as past attempts have. Medicare absolutely should pay less for prescription drugs. But it will probably continue to pay excessive prices — because that is its nature.”

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement